Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

CVS Pharmacy is pulling all containers of Johnson & Johnson's 22-ounce baby powder after the FDA found sub-trace levels of asbestos, the pharmacy chain announced Thursday.

CVS pulls all J&J 22 ounce baby powder from shelves after FDA finds sub-trace levels of asbestos

Pharmacy retailer CVS Health Corp  said on Thursday it is pulling out 22 ounce bottles of Johnson & Johnson's  baby powder from its stores as a precautionary measure.

CVS pulls out 22 ounce J&J baby powder from stores

Atlas Air Worldwide

Kinder Morgan

Buffett is a huge fan of strong cash generation at a reasonable price.

3 Stocks 'Warren Buffett' Would Love

The drones are coming — and they're bringing your aspirin.

CVS to test drone delivery for your medications

ATLANTA, Oct.  21, 2019  (GLOBE NEWSWIRE) --     UPS   (NYSE:UPS) subsidiary  UPS Flight Forward Inc .  (UPSFF) and  CVS Health Corp   oration  (NYSE:CVS.N) subsidiary CVS Pharmacy, Inc. today announced they have agreed to develop a variety of drone delivery use cases, including business-to-consumer operating models.

UPS Flight Forward, CVS Pharmacy to Develop Drone Delivery Applications

The project is just getting started, but could result in CVS stores doubling as drone delivery hubs.

UPS and CVS team up to develop drone deliveries right to your house

UPS Flight Forward and its partner Matternet this month became the first drone delivery service to receive full certification from the FAA to operate a drone airline.

UPS partners with CVS to develop drone delivery service for prescription drugs

Walgreens

With UPS and Google sister company Wing as partners, the big pharmacies are starting to deliver pills, Cheez-Its, and first aid supplies by drone.

CVS and Walgreens’s drones are finally here—and they’re bringing Band-Aids

Two online recruitment firms have exposed more than 200,000 CVs, revealing job-hunters' names, addresses, phone numbers and career histories to potential cyber criminals, Sky News can reveal.

Revealed: Hundreds of thousands of CVs exposed online

Bristol-Myers

Caterpillar

Skyworks Solutions

Trade talk optimism sent stocks, especially trade sensitive ones, soaring on Thursday and Friday.

The Best Dividend Stocks To Buy With Trade Uncertainty This High

Bed Bath & Beyond

Crocs

GameStop

JD.com

Micron Technology

Snap

Stage Stores

Target

These hot stocks are in the midst of impressive turnarounds over the past several months, and deserve your attention.

10 Hot Stocks Staging Huge Reversals

Shares of CVS have rebounded off lows but still offer excellent value to investors.

CVS Is Still A Great Buy

Management is executing well on the Aetna merger which creates a potentially strong short-term catalyst.

3 Reasons CVS Could Keep Roaring Higher

British American Tobacco

Carnival

Lowe's

The September jobs report showed slowing job creation, but also the lowest unemployment since December 1969.

The Best Dividend Stocks To Buy During The Strongest Job Market In 50 Years

Though CVS's acquisitions get a lot of press, the company's stores are a focus for good reason.

3 Reasons CVS Offers Healthy Growth

CVS Health (CVS) closed the most recent trading day at $61.99, moving -0.4% from the previous trading session.

CVS Health (CVS) Stock Moves -0.4%: What You Should Know

Bank of America

Booz Allen Hamilton Hld

Cigna

Chevron

CoreCivic

GEO Group

Alphabet

Gap Inc

Lockheed Martin

Northrop Grumman

Papa John's

Wells Fargo

Exxon Mobil

J.P. Morgan's list includes U.S. companies that would be affected by policy initiatives in areas like anti-trust, financial regulation, climate change, healthcare reform and minimum wage, among others.

These stocks could have the most to lose if a progressive Democratic agenda takes hold in 2020

Walgreens is the latest retailer to suspend sales of Sanofi's heartburn medication Zantac and other generic ranitidine products while the U.S. Food and Drug Administration reviews their safety.

Walgreens joins CVS in suspending sales of heartburn medicine Zantac during safety review

CVS Health Corp will stop selling the popular heartburn drug Zantac after traces of a known carcinogen were found in some of the products by the US Food and Drug Administration. The pharmacy giant said Saturday it’s suspended sales of Zantac, as well as its own generic ranitidine products, out of “an abundance of caution”.

CVS pulls Zantac over link to cancer-causing compound

CVS said it will discontinue sales the popular Zantac heartburn treatment and its own generic ranitidine products from its pharmacies after traces of a known carcinogen were found in some of the products by the U.S. Food and Drug Administration.

CVS suspends sales of Zantac brand and generic heartburn drug during safety review

The FDA said it found traces of a known carcinogen in Zantac and its generic equivalents.

CVS Suspends Sale Of Popular Heartburn Drug Zantac Over Possible Cancer Link

McKesson

Walmart

Increasing lawsuits against pharmaceutical companies are likely to impact retailers and distributors.

Opioid Overdose Crisis in US Likely to Affect These 3 Stocks

CVS Health has been one of the pharma companies I've been following and where I've been expecting a rebound for some time.

CVS Health - Why The Discount Is Thinning

Cardinal Health

Mallinckrodt PLC

Teva Pharmaceutical

The health care industry could be forced to pay out as much as $150 billion.

5 Stocks That Could Get Crushed By Opioid Lawsuit Tidal Wave

The company is encouraging employers to provide a sleep app that could help push digital therapeutics into the mainstream.

News for CVS Health Stock (CVS)